What is the price target for NOV stock?
24 analysts have analysed NOV and the average price target is 20.19 USD. This implies a price increase of 8.06% is expected in the next year compared to the current price of 18.68.
NYSE:NOV • US62955J1034
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NOV INC (NOV).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-04 | Goldman Sachs | Maintains | Sell -> Sell |
| 2026-02-11 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-02-09 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2026-02-09 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2026-02-06 | Stifel | Maintains | Buy -> Buy |
| 2026-02-04 | Barclays | Upgrade | Underweight -> Equal-Weight |
| 2026-01-07 | TD Cowen | Maintains | Buy -> Buy |
| 2026-01-07 | Susquehanna | Maintains | Positive -> Positive |
| 2025-12-18 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-12-17 | Barclays | Maintains | Underweight -> Underweight |
| 2025-12-11 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-11-12 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-11-11 | Barclays | Maintains | Underweight -> Underweight |
| 2025-11-05 | Goldman Sachs | Maintains | Sell -> Sell |
| 2025-10-30 | Barclays | Maintains | Underweight -> Underweight |
| 2025-10-29 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-29 | Stifel | Maintains | Buy -> Buy |
| 2025-10-08 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-08-14 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-07-30 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-07-30 | Susquehanna | Maintains | Positive -> Positive |
| 2025-07-30 | Stifel | Maintains | Buy -> Buy |
| 2025-07-30 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2025-07-30 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2025-07-16 | Stifel | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 8.583B 18.60% | 8.87B 3.34% | 8.744B -1.42% | 8.727B -0.19% | 8.991B 3.03% | 9.377B 4.29% | 9.264B -1.21% | 9.291B 0.29% | |
| EBITDA YoY % growth | 953M 68.67% | 1.222B 28.23% | 1.032B -15.55% | 1.003B -2.81% | 1.098B 9.47% | 1.183B 7.74% | 1.172B -0.93% | 1.147B -2.13% | |
| EBIT YoY % growth | 651M 146.59% | 879M 35.02% | 677M -22.98% | 656.65M -3.01% | 746.8M 13.73% | 829.78M 11.11% | N/A | N/A | |
| Operating Margin | 7.58% | 9.91% | 7.74% | 7.52% | 8.31% | 8.85% | N/A | N/A | |
| EPS YoY % growth | 1.28 132.73% | 1.61 25.78% | 0.57 -64.72% | 1.04 82.43% | 1.27 22.88% | 1.59 24.76% | 1.52 -4.63% | 1.48 -2.00% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.20 3.23% | 0.24 -17.64% | 0.30 175.85% | 0.32 1,536.95% | 0.29 48.95% | 0.35 46.42% | 0.38 25.07% | 0.39 22.60% | 0.37 25.84% | 0.39 10.32% | 0.40 4.86% |
| Revenue Q2Q % growth | 2.09B -0.62% | 2.131B -2.61% | 2.197B 0.97% | 2.262B -0.66% | 2.108B 0.86% | 2.221B 4.22% | 2.265B 3.10% | 2.339B 3.40% | N/A | N/A | N/A |
| EBITDA Q2Q % growth | 217.18M -14.50% | 238.81M -29.35% | 256.73M -41.25% | 269.77M -47.00% | 242.6M 11.70% | 269.56M 12.88% | 281.82M 9.77% | 283.5M 5.09% | 263.25M 8.51% | 271.9M 0.87% | 277.21M -1.64% |
| EBIT Q2Q % growth | 131.7M -20.18% | 149.88M -7.48% | 168.03M -2.31% | 179.26M 16.40% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
24 analysts have analysed NOV and the average price target is 20.19 USD. This implies a price increase of 8.06% is expected in the next year compared to the current price of 18.68.
NOV INC (NOV) will report earnings on 2026-04-27, after the market close.
The consensus EPS estimate for the next earnings of NOV INC (NOV) is 0.2 USD and the consensus revenue estimate is 2.09B USD.
The consensus rating for NOV INC (NOV) is 71.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.